Skip to main content
Clinical Trials/NCT01580436
NCT01580436
Unknown
N/A

Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery

Hasselt University1 site in 1 country300 target enrollmentAugust 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Tricuspid Valve Insufficiency
Sponsor
Hasselt University
Enrollment
300
Locations
1
Primary Endpoint
combination of all-cause mortality or heart failure hospitalisation
Last Updated
11 years ago

Overview

Brief Summary

De novo or progressive tricuspid regurgitation (TR) is not uncommonly observed following mitral valve surgery and associated with worse outcome. Hence, concomitant tricuspid valve annuloplasty (TVP) has been recommended for patients undergoing mitral valve surgery when tricuspid annular dilatation is present even in absence of significant TR. However, whether such a strategy of "prophylactic TVP" results in improved outcomes has not been shown to date by a prospective randomized study. The investigators goal is therefore to initiate such a study and evaluate the effect of concomitant TVP on mid- and long-term outcome in patients scheduled for mitral valve surgery and tricuspid annular dilatation but <2+ TR.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
December 2017
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Hasselt University
Responsible Party
Principal Investigator
Principal Investigator

Wilfried Mullens, MD PhD

Professor Cardiovascular Physiology

Hasselt University

Eligibility Criteria

Inclusion Criteria

  • Scheduled for mitral valve surgery
  • Tricuspid Annular diameter \> 40mm or \>21mm/m²

Exclusion Criteria

  • Tricuspid Regurgitation more than 2+
  • Unable to provide informed consent

Outcomes

Primary Outcomes

combination of all-cause mortality or heart failure hospitalisation

Time Frame: at 12 months post-surgery

Secondary Outcomes

  • Duration of Hospital and ICU stay(postoperative phase)
  • progressive TR > 2+ post-surgery(3, 6, 12 and 18 months)
  • Quality of Life(6, 12 and 18 months)
  • cardiovascular mortality(at 3, 6, 12 and 18 months post-surgery)
  • RV function & geometry(3, 6, 12 and 18 months)
  • All-Cause Mortality(at 3, 6, 12 and 18 months post-surgery)
  • Hospitalization for Heart Failure(at 3, 6, 12 and 18 months post-surgery)
  • Exercise Tolerance(6, 12 and 18 months)

Study Sites (1)

Loading locations...

Similar Trials